Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06136767 · ClinicalTrials.gov registry record

Registry for Systemic Eczema Treatments

A clinical trial of Atopic Dermatitis, sponsored by Johns Hopkins University.

Recruiting
Registry status
400
Enrollment target
1
Study location

NCT06136767: Recruiting study of Atopic Dermatitis, sponsored by Johns Hopkins University.

NCT06136767 is a study of Atopic Dermatitis that is actively recruiting participants, run by Johns Hopkins University. The registered enrollment target is 400 participants, below the 607-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (34% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06136767, a study of Atopic Dermatitis, is actively recruiting participants, sponsored by Johns Hopkins University.

RECRUITING
Registry status
400 participants
Enrollment target
1
Study location

Study Summary

The Registry for Systemic Eczema Therapies (RESET) registry is a database and biospecimen repository for patients with pediatric-onset atopic dermatitis (AD) who have used or will initiate any systemic treatment(s) for AD. The goal of the registry is to enable more efficient research recruitment and data collection as well as timely notification to enrollees about newly FDA-approved treatments for AD.

Primary Outcome

To evaluate the clinical effectiveness of systemic treatments for atopic dermatitis according to IGA through periodic electronic medical record (EMR) review. The IGA is a physician-reported atopic dermatitis severity score. IGA is the global clinical assessment scale to determine severity of AD and clinical response to treatment on a static 5-point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on the degree of erythema and papulation/infiltration. The IGA score ra

Conditions Studied

Study Locations (1)

Maryland

  • Johns Hopkins University - Baltimore

Trial Details

FieldValue
Enrollment Target 400 participants
Start Date 2024-01-17
Est. Completion 2030-12-31
Johns Hopkins University

1,448 total trials

What NCT06136767 shows while recruiting

NCT06136767 is an observational study that tracks outcomes without assigning an intervention. The registered 400 participants enrollment target is mid-sized for trials with a published cap, below the 607-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (34% lower).

The record links to 1 condition, with Atopic Dermatitis appearing as the primary indexed condition, and to 0 interventions.

NCT06136767 reports a single indexed study location in Maryland.

Frequently Asked Questions

What is clinical trial NCT06136767 about?

NCT06136767 is a clinical study titled "Registry for Systemic Eczema Treatments". The Registry for Systemic Eczema Therapies (RESET) registry is a database and biospecimen repository for patients with pediatric-onset atopic dermatitis (AD) who have used or will initiate any systemic treatment(s) for AD. The goal of the registry is to enable more efficient research recruitment and...

What is the current status of trial NCT06136767?

This trial is currently recruiting. The enrollment target is 400 participants. The study started on 2024-01-17. Estimated completion is 2030-12-31.

What conditions does trial NCT06136767 study?

This clinical trial studies the following conditions: Atopic Dermatitis.

Who is sponsoring clinical trial NCT06136767?

This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06136767 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Atopic Dermatitis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06136767's enrollment target sits among peer trials

400 33rd of 150 higher than 117 of 150 other Atopic Dermatitis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Atopic Dermatitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01665326 · 400 participants

    Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease

  • NCT02108054 · 400 participants · NA

    Behavioral and Functional Task Development, Implementation, and Testing

  • NCT02216500 · 400 participants · NA

    Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy

  • NCT02250352 · 400 participants

    Core Biopsies for Establishing a Breast Tumor Tissue Repository

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06136767, the US trial registry maintained by the National Library of Medicine. NCT06136767 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.